Literature DB >> 3849981

Skin tests with autologous cholesteryl hemisuccinate treated tumour cells in cancer patients.

M Munzarová, D Zemanová, J Kovarik, A Rejthar, Z Pacovsky.   

Abstract

Skin tests with autologous irradiated tumour cells were performed in 20 malignant melanoma, 7 breast and 6 ovarian cancer patients. In the majority of cases evident reaction was noted with cholesteryl hemisuccinate (CHS)-treated cells while the reaction with untreated cells was mostly negative. No correlation was found between this reactivity and the ability of patients to be sensitized to DNCB and to their reactivity to PPD. No correlation was found between reactivity to CHS-treated tumour cells and the stage and course of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3849981     DOI: 10.1007/bf00205686

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  Immunological skin testing and interpretation: a plea for uniformity.

Authors:  S E Bates; J Y Suen; B L Tranum
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

2.  Lipids and lymphocyte function.

Authors:  K N Traill; G Wick
Journal:  Immunol Today       Date:  1984-03

3.  Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity.

Authors:  M Shinitzky; Y Skornick; N Haran-Ghera
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

Review 4.  Basophils in human disease.

Authors:  E B Mitchell; P W Askenase
Journal:  Clin Rev Allergy       Date:  1983-09

5.  Induction of delayed hypersensitivity reactions in cancer patients by cholesterol-hemisuccinate-treated autologous tumor cells.

Authors:  Y Skornick; A R Dresdale; W F Sindelar
Journal:  J Natl Cancer Inst       Date:  1983-03       Impact factor: 13.506

  5 in total
  1 in total

1.  Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.

Authors:  M Munzarová; D Zemanová; J Kovarík; Z Pacovský; A Rejthar; J Bártek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.